TY - JOUR
T1 - Discussion
T2 - DMARDs and biologic therapies in the management of inflammatory joint diseases
AU - Vaz, Austin
AU - Lisse, Jeffrey
AU - Rizzo, Warren
AU - Albani, Salvatore
N1 - Funding Information:
Austin Vaz has received clinical research grants from Centocor, Genentech, Roche, BMS and Amgen. He has served as a consultant for Abbott, BMS and UCB. Jeffrey Lisse has received clinical research grants from Centocor. Salvatore Albani is the inventor of dnaJP1 technology, which is owned by the University of California. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2009
Y1 - 2009
N2 - Therapy for inflammatory joint diseases, such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, includes various conventional disease-modifying antirheumatic drugs (DMARDs). These therapeutic agents are termed DMARDs because they have the potential to reduce or prevent joint damage and preserve joint integrity and function. Conventional DMARDs are used as monotherapy or in combination and include methotrexate, leflunomide, azathioprine, ciclosporin, hydroxychloroquine, sulfasalazine, gold and minocycline. Biologic response modifiers, which are based on proteins made by living cells, are newer agents available for the treatment of various inflammatory joint diseases. Biologic therapies now approved for use in inflammatory joint diseases are TNF inhibitors, T-cell modulators and B-cell depleters. They have all been shown to have clinical efficacy and are able to retard structural damage. However, all current immune-modulating therapies also have potential side effects, and the decision to use a particular agent for treatment should be based on a thorough discussion of the benefits and risks with the patient. Newer biologic response modifiers and other immunologic therapies are currently being developed for the treatment of inflammatory joint diseases and are discussed in this review.
AB - Therapy for inflammatory joint diseases, such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, includes various conventional disease-modifying antirheumatic drugs (DMARDs). These therapeutic agents are termed DMARDs because they have the potential to reduce or prevent joint damage and preserve joint integrity and function. Conventional DMARDs are used as monotherapy or in combination and include methotrexate, leflunomide, azathioprine, ciclosporin, hydroxychloroquine, sulfasalazine, gold and minocycline. Biologic response modifiers, which are based on proteins made by living cells, are newer agents available for the treatment of various inflammatory joint diseases. Biologic therapies now approved for use in inflammatory joint diseases are TNF inhibitors, T-cell modulators and B-cell depleters. They have all been shown to have clinical efficacy and are able to retard structural damage. However, all current immune-modulating therapies also have potential side effects, and the decision to use a particular agent for treatment should be based on a thorough discussion of the benefits and risks with the patient. Newer biologic response modifiers and other immunologic therapies are currently being developed for the treatment of inflammatory joint diseases and are discussed in this review.
KW - Biologic response modifier
KW - Disease-modifying antirheumatic drug
KW - Methotrexate
KW - Rheumatoid arthritis
KW - TNF inhibitor
UR - http://www.scopus.com/inward/record.url?scp=77649107244&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77649107244&partnerID=8YFLogxK
U2 - 10.1586/eci.09.14
DO - 10.1586/eci.09.14
M3 - Review article
C2 - 20477007
AN - SCOPUS:77649107244
VL - 5
SP - 291
EP - 299
JO - Expert Review of Clinical Immunology
JF - Expert Review of Clinical Immunology
SN - 1744-666X
IS - 3
ER -